Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1

Journal of Medicinal Chemistry

Volumn 42, Issue 15, 1999, Pages 2752-2759

  Quan, Mimi L ^a   Liauw, Ann Y ^a   Ellis, Christopher D ^a   Pruitt, James R ^a   Carini, David J ^a   Bostrom, Lori L ^a   Huang, Peggy P ^a   Harrison, Kimberly ^a   Knabb, Robert M ^a   Thoolen, Martin J ^a   Wong, Pancras C ^a   Wexler, Ruth R ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 [3 (AMINOIMINOMETHYL)PHENYL] 5 [[2' (AMINOSULFONYL)[1,1' BIPHENYL] 4 YL]AMINO]CARBONYL] 4,5 DIHYDRO 5 ISOXAZOLEACETIC ACID METHYL ESTER; 3 [3 (AMINOIMINOMETHYL)PHENYL] 5 [[5 2' (AMINOSULFONYL)PHENYL] 2 PYRIMIDINYL]AMINO]CARBONYL] 4,5 DIHYDRO 5 ISOXAZOLEACETIC ACID METHYL ESTER; ACETYL DEXTRO PHENYLALANYLPROLYLBOROARGININE; BLOOD CLOTTING FACTOR 10A INHIBITOR; ISOXAZOLINE DERIVATIVE; SF 324; UNCLASSIFIED DRUG; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; DRUG SYNTHESIS; INHIBITION KINETICS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RABBIT;

EID: 0033615010     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980405i     Document Type: Article

References (26)

1. This work was partially presented at the 215th ACS National Meeting: Quan, M. L. Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 215th ACS National Meeting, Dallas, TX, March 29-April 2, 1998; Abstract 202.
2. Ripka, W. C.; Vlasuk, G. P. Antithrombotics/Serine Proteases. In Annual Reports in Medicinal Chemistry: Bristol, J. A., Ed.; Academic Press: New York, 1997; Vol. 32, pp 71-89.
3. Davre, E. W.; Fujikawa, K.; Kisiel, W. The Coagulation Cascade: Initiation, Maintenance and Regulation. Biochemistry 1991, 30, 10363-10370.
4. Elodi, S.; Varadi, K. Optimization of Conditions for the Catalytic Effect of the Factor IXa-Factor VIII Complex: Probable Role of the Complex in the Amplication of Blood Coagulation. Thromb. Res. 1979, 15, 617-629.
5. Harker, L. A.; Hanson, S. R.; Kelly, A. B. Antithrombotic Strategies Targeting Thrombin Activities, Thrombin Receptors and Thrombin Generation. Thromb. Haemostasis 1997, 78, 736-741.
6. Tidwell, R. R.; Webster, W. P.; Shaver, S. R.; Geratz, J. D. Strategies for Anticoagulation with Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors. Thromb. Res. 1980, 19, 339-349.
7. Stürzebecher, J.; Markwardt, F.; Walsmann, P. Synthetic Inhibitors of Serine Proteinases XIV. Inhibition of Factor Xa by Derivatives of Benzamidine. Thromb. Res. 1976, 9, 637-646.
8. Stürzebecher, J.; Markwardt, F.; Walsmann, P. Synthetic Inhibitors of Serine Proteinases XXIII. Inhibition of Factor Xa by Diamidines. Thromb. Res. 1980, 17, 545-548.
9. Nagahara, T.; Yukoyama, Y.; Inamura, K.; Katakura, S.; Komoriya, S.; Yamaguchi, H.; Hara, T.; Iwamoto, M. Dibasic (amidinoaryl)propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors. J. Med. Chem. 1994, 37, 1200-1207.
10. Nagahara, T.; Yukoyama, Y.; Inamura, K.; Katakura, S.; Komoriya, S.; Yamaguchi, H.; Hara, T.; Iwamoto, M. Design, Synthesis and Biological Activities of Orally Active Coagulation Factor Xa Inhibitors. Eur. J. Med. Chem. 1995, 30, 139s.
11. Sato, K.; Kawasaki, T.; Taniuchi, Y.; Hisamichi, N.; Koshio, H.; Matsumoto, Y. YM-60828, a Novel Factor Xa Inhibitor: Separation of its Antithrombotic Effects from its Prolongation of Bleeding Time. Eur. J. Pharmacol. 1997, 339, 141-146.
12. Taniuchi, Y.; Sakai, Y.; Hisamichi, N.; Kayama, M.; Mano, Y.; Sato, K.; Hirayama, F.; Koshio, H.; Matsumoto, Y.; Kawasaki, T. Biochemical and Pharmacological Characterization of YM-60828, a Newly Synthesized and Orally Active Inhibitor of Human Factor Xa. Thromb. Haemostasis 1998, 79, 543-548.
13. Sato, K.; Kawasaki, T.; Hisamichi, N.; Taniuchi, Y.; Hirayama, F.; Koshio, H.; Matsumoto, Y. Antithrombotic Effects of YM-60828, a Newly Synthesized Factor Xa Inhibitor, in Rat Thrombosis Model and its Effects on Bleeding Time. Br. J. Pharmacol. 1998, 123, 92-96.
14. Maduskuie, T. P., Jr.; McNamara, K. J.; Ru, Y.; Knabb, R. M.; Stouten, P. F. W. Rational Design and Synthesis of Novel, Potent Bis-Phenylamidine Carboxylate Factor Xa Inhibitors. J. Med. Chem. 1998, 41, 53-62.
15. Quan, M. L.; Pruitt, J. R.; Ellis, C. D.; Liauw, A. Y.; Galemmo, R. A., Jr.; Stouten, P. F. W.; Wityak, J.; Knabb, R. M.; Thoolen, M. J.; Wong, P. C.; Wexler, R. R. Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 2813-2818.
16. Wong, P. C.; Crain, E. J., Jr.; Nguan, O.; Watson, C. A.; Racanelli, A. Antithrombotic Actions of Selective Inhibitors of Blood Coagulation Factor Xa in Rat Models of Thrombosis. Thromb. Res. 1996, 83, 117-126.
17. Boykin, D. W.; Kumar, A.; Hall, J. E.; Bender, B. C.; Tidwell, R. R. Anti-Pneumocystis Activity of Bis-amidoximes and Bis-o-alkylamidoximes Prodrugs. Bioorg. Med. Chem. Lett. 1996, 6, 3017-3020.
18. At the time this work was carried out, there were no published reports on monobasic FXa inhibitors. Subsequently, the following manuscripts have published: (a) Klein, S. I.; Czekaj, M.; Gardner, C. J.; Guertin, K. R.; Cheney, D. L.; Spada, A. P.; Bolton, S. A.; Brown, K.; Colussi, D.; Heran, C. L.; Morgan, S. R.; Leadley, R. J.; Dunwiddie, C. T.; Perrone, M. H.; Chu, V. Identification and Initial Structure-Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa. J. Med. Chem. 1998, 41, 437-450.
19. (b) Phillips, G. B.; Buckman, B. O.; Davey, D. D.; Eagen, K. A.; Guilford, W. J.; Hinchman, J.; Ho, E.; Koovakkar, A. L.; Light, D. R.; Mohan, R.; Ng, H. P.; Post, J. M.; Shaw, K. J.; Smith, D.; Subramanyam, B.; Sullivan, M. E.; Trinh, L.; Verona, R.; Walters, J.; White, K.; Whitlow, M.; Wu, S.; Xu, W.; Morrissey, M. M. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydro-1-methyl-(1H-imidazol-2-yl)phenoxy]pyridin- 4-yl]-N-methylglycine (ZK-807834): A Potent, Selective, and Orally Active Inhibitor of the Blood Coagulation Enyme Factor Xa. J. Med. Chem. 1998, 41, 3557-3562.
20. Miyaura, N.; Yanagi, T.; Suzuki, A. The Palladium-catalyzed Cross-coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of Bases. Synth. Commun. 1981, 11, 513-519.
21. Quan, M. L.; Wityak, J.; Dominguez, C.; Duncia, J. V.; Kettner, C. A.; Ellis, C. D.; Liauw, A. Y.; Park, J. M.; Santella, J. B.; Knabb, R. M.; Thoolen, M. J.; Weber, P. C.; Wexler, R. R. Biaryl Substituted Alkylboronate Esters as Thrombin Inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 1595-1600.
22. Padmanabhan, K.; Padmanabhan, K. P.; Tulinsky, A.; Park, C. H.; Bode, W.; Huber, R.; Blankenship, D. T.; Cardin, A. D.; Kisiel, W. Structure of Human Des(1-45) Factor Xa at 2.2 Å Resolution. J. Mol. Biol. 1993, 232, 947-966.
23. 4 pocket using Sybyl 6.22 (Tripos Inc., St. Louis, MO). The structure was further refined by energy minimization keeping the protein rigid and the inhibitor completely flexible. The force field is described by Clark, M.; Cramer, R. D., III; Van Opdenbosch, N. Validation of the General Purpose Tripos 5.2 Force Field. J. Comput. Chem. 1989, 10, 982-1012.
24. Knabb, R. M.; Kettner, C. A.; Timmermans, P. B. M. W. M.; Reilly, T. M. In Vivo Characterizations of a Synthetic Thrombin Inhibitor. Thromb. Haemostasis 1992, 67, 56-59.
25. Kettner, C. A.; Mersinger, L. J.; Knabb, R. M. The Selective Inhibition of Thrombin by Peptides of Boroarginine. J. Biol. Chem. 1990, 265, 18289-18297.
26. Liu, K. C.; Shelton, B. R.; Howe, R. K. Particularly Convenient Preparation of Benzohydroximinoyl Chlorides (Nitrile Oxide Precursors). J. Org. Chem. 1980, 45, 3916-3918.